Addinex Technologies Awarded $260K Grant by the CDC to Improve Addiction Medication Dispensing
September 07, 2022 08:00 ET
|
Addinex Technologies, Inc.
NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Addinex Technologies, Inc., a healthcare technology company focused on the innovation of medication dispensing, has been awarded a $260K Phase I Small...
Apotheca Biosciences (PCFP) Overviews Pain-Patch, an Opioid Substitution
September 17, 2018 08:02 ET
|
Apotheca Biosciences
Saint Petersburg, FL, Sept. 17, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Apotheca Biosciences (OTC PINK: PCFP), a developer of cutting-edge medical products, nutraceuticals, drug formulations...
Schuyler County Opioid Lawsuit Fight Continues Forward
February 22, 2018 17:18 ET
|
Napoli Shkolnik PLLC
WATKINS GLEN, NY--(Marketwired - February 22, 2018) - Schuyler County will hold a public hearing on March 12 to review a proposed local law declaring the opioid epidemic and its effects on the County...
Elite Pharmaceuticals Files ANDA for Oxycodone Hydrochloride Extended Release
September 20, 2017 08:37 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) announced that it has filed an Abbreviated New Drug Application (ANDA) with...
Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study for a Generic OxyContin®
January 17, 2017 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported positive topline results from a pivotal bioequivalence fed study...
Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for ELI-201
July 15, 2014 10:31 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., July 15, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in healthy...
Elite Pharmaceuticals Reports Results of Pilot Bioequivalence Study for ELI-201
February 18, 2014 07:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 18, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) announced today successful results from a pilot bioequivalence study...
Elite Pharmaceuticals Announces Bridge Loan Facility
October 16, 2013 07:45 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Oct. 16, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) announced today that it has entered into a credit line agreement ("Credit Line") with Nasrat...
Elite Pharmaceuticals, Inc. Appoints Nasrat Hakim as President and Chief Executive Officer
August 05, 2013 07:00 ET
|
Elite Pharmaceuticals, Inc.
Elite Adds Twelve Approved Products to Its Pipeline
Conference Call Scheduled for 1 PM Eastern Time
NORTHVALE, N.J., Aug. 5, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP)...
NEXAFED(TM) Pseudoephedrine Tablets Disrupt Methamphetamine Production
March 02, 2012 06:30 ET
|
Acura Pharmaceuticals
PALATINE, IL--(Marketwire - Mar 2, 2012) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced independent laboratory...